ArticleBMC cancer2021

An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations.

Keunchil Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.